Consistent with previous reports that miR-134 has oncogenic activity in head and neck carcinoma and in lung adenocarcinoma,9, 10, 11 we demonstrated that miR-134 acts as an oncogene to amplify the ERK/JNK signaling pathways in ovarian cancer cells. This evidence concerns the gene MAPK8 and lung adenocarcinoma.